• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600201.SS
Share

Jinyu Bio-technology Co., Ltd. Stocks

CN¥ 11.71Last Updated 11.09.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 2.03B

CN¥ 11.71
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Hohhot, China, Jinyu Bio-technology Co., Ltd. is a Chinese firm specializing in the development, production, and commercialization of biological products for animal health. Established in 1992, the company provides crucial vaccines designed to combat diseases such as foot-and-mouth disease, highly pathogenic avian influenza, brucellosis, rabies, and swine fever. These vital immunizations are supplied for a broad spectrum of animals, including pigs, poultry, ruminants, and companion pets. The entity formally adopted its current name, Jinyu Bio-technology Co., Ltd., in December 2015, having previously operated as Inner Mongolia Jinyu Group Co., Ltd.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 600201.SS is 15.3 and suggests 25.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.09.2026 17:37

Inflation in the U.S. in August came in slightly above expectations. What can we expect from the Fed now?

11.09.2026 17:24

"A Recipe for Volatility": Why BofA Sees Risks in Market Calm

11.09.2026 15:00

Uber's CEO Invested $10 Million in the Company's Shares, Which Had Fallen in Price

11.09.2026 13:30

An investor from "Shorting" advised buying wine amid the dollar's decline

11.09.2026 13:11

Diesel prices in the U.S. have exceeded $6 per gallon for the first time in history

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026